Known for strategic thinking with the ability to lead across entire life cycle of drugs, my experience spans clinical research, regulatory affairs, sales, marketing, market access, and geographic expansion. I have successfully led multiple integrations and scaled organizations from ground-up.
Company culture and helping patients live better lives fuel my passion. I am skilled at creating and developing strong connected and high performing teams with a collaborative, transparent, and charismatic style. I am adept at working across and impacting large, cross-functional teams.
I am an active Board Member in industry associations and have served on community organization boards.
Agenda: Day 1 Oct 5, 2020
INDUSTRY EXPERT - PDCI
TO LAUNCH OR NOT TO LAUNCH, THAT IS THE QUESTION!
Canada ranks 10th out of 14 countries on its attractiveness for new medicine launch according to PDCI’s 2022 Biopharmaceutical Ecosystem Index. To ensure Canadian patients gain access to the new medicines of the future, we must keep pace with how constantly evolving local and international market access landscapes will affect Canada’s relative attractiveness for launch in the years to come. Develop your advocacy plan by:
- Learning how Canada currently stacks up on its Development & Commercialization Infrastructure, Regulatory Landscape, and Market Access Environment
- Identifying the policy areas that could most effectively improve our relative attractiveness
- Discussing what Canada’s attractiveness rankings mean to Canadian patients
Share perspectives with your senior management that can help make a difference in future new drug launches
Agenda: Day 2 Oct 6, 2020